Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • P454: ACUTE MYELOID LEUKEMIA (...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
P454: ACUTE MYELOID LEUKEMIA (AML) WITH IDH1 AND IDH2 MUTATIONS CAN BE EFFECTIVELY RISK STRATIFIED BASED ON THE PRESENCE ADVERSE RISK GENOMIC FEATURES.

P454: ACUTE MYELOID LEUKEMIA (AML) WITH IDH1 AND IDH2 MUTATIONS CAN BE EFFECTIVELY RISK STRATIFIED BASED ON THE PRESENCE ADVERSE RISK GENOMIC FEATURES.

Bibliographic Details
Main Authors: Aniket Bhide, Gaurav Chatterjee, Sweta Rajpal, Swapnali Joshi, Vishram Terse, Dhanlaxmi Shetty, Anant Gokarn, Sachin Punatar, Nishant Jindal, Bhausaheb Bagal, Lingaraj Nayak, Hasmukh Jain, Navin Khattry, Manju Sengar, Prashant Tembhare, Sumeet Gujral, Papagudi Subramanian, Nikhil Patkar
Format: Article
Language:English
Published: Wiley 2023-08-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/01.HS9.0000968724.09323.c5
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://journals.lww.com/10.1097/01.HS9.0000968724.09323.c5

Similar Items

  • BRAFV600E mutation in hairy cell leukemia: A single-center experience
    by: Asma Bibi, et al.
    Published: (2018-01-01)
  • P360: MEASURABLE/MINIMAL RESIDUAL DISEASE (MRD) STATUS IS THE MOST RELEVANT INDICATOR OF CLINICAL OUTCOME IN MIXED PHENOTYPIC ACUTE LEUKEMIAS (MPAL)
    by: Prashant Tembhare, et al.
    Published: (2023-08-01)
  • Circulating tumor plasma cells and peripheral blood measurable residual disease assessment in multiple myeloma patients not planned for upfront transplant
    by: Prashant R. Tembhare, et al.
    Published: (2024-04-01)
  • Utility of Immunophenotypic Measurable Residual Disease in Adult Acute Myeloid Leukemia—Real-World Context
    by: Nikhil Patkar, et al.
    Published: (2019-06-01)
  • Immunogenetics of chronic lymphocytic leukemia
    by: Nikhil Patkar, et al.
    Published: (2017-01-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs